Impact of HER2 Expression on the Prognosis of Muscle-Invasive Bladder Cancer Patients Treated with Bladder-Preservation Comprehensive Therapy
Abstract Background HER2 expression has been confirmed to be associated with bladder cancer aggressiveness. Anti-HER2 RC48-ADC is approved in China for the treatment of patients with advanced urothelial carcinoma with failed chemotherapy who are HER2 positive (IHC 2 + or 3 +). The discovery of HER2...
Saved in:
Main Authors: | Yatong Chen, Fei Luo, Tingji Zhang, Jian Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Biological Procedures Online |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12575-025-00261-w |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer
by: Jingxian Li, et al.
Published: (2025-01-01) -
Real-world data on utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer: impact on surgical complications and oncological efficacy
by: Hege S. Haugnes, et al.
Published: (2025-01-01) -
Trimodal organ‑preserving treatment of muscle‑invasive bladder cancer
by: A. V. Troianov, et al.
Published: (2023-03-01) -
3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer
by: R.S. Chystiakov, et al.
Published: (2023-06-01) -
Nucleotide variation in Foxp3 gene and prognosis of bladder cancer: a case-control study
by: Qin Li, et al.
Published: (2025-01-01)